CBIO · XBRL financial data
Crescent Biopharma financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | — | — | — | — | — | 10,844 |
| Research and development | 44,929 | 47,492 | 28,391 | 20,072 | 14,260 | 138,086 |
| General and administrative | 16,743 | 17,115 | 19,087 | 19,214 | 18,249 | 25,390 |
| Total operating expenses | 61,672 | 64,607 | 47,478 | 39,285 | 40,039 | 163,476 |
| Operating income (loss) | (51,509) | (63,447) | (47,403) | (39,275) | (40,039) | (152,632) |
| Interest expense | — | — | — | — | — | 2,185 |
| Income tax expense (benefit) | — | — | — | — | — | 2,000 |
| Net income (loss) | (51,027) | (63,427) | (46,689) | (36,899) | (37,879) | (153,942) |
| Earnings per share, basic‡ USD per share | (112.00) | (123.00) | (89.00) | (58.00) | (59.00) | — |
| Earnings per share, diluted‡ USD per share | (112.00) | (123.00) | (89.00) | (58.00) | (59.00) | — |
| Weighted average shares, basic‡ thousands of shares | 457 | 515 | 525 | 633 | 645 | — |
| Weighted average shares, diluted‡ thousands of shares | 457 | 515 | 525 | 633 | 645 | — |
- ‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (June 2025); filings made before it reported them unadjusted.
- † Share count changed about 43x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (CBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 137,035 | 90,255 | 47,871 | 41,793 | 10,720 | 213,192 |
| Accounts receivable | — | — | — | — | 0 | 18,000 |
| Prepaid and other current assets | 1,238 | 534 | 2,844 | 1,998 | 371 | 5,463 |
| Total current assets | 138,273 | 90,789 | 50,715 | 43,791 | 11,091 | 236,655 |
| Property and equipment, net | 621 | 369 | 242 | — | 0 | 846 |
| Right-of-use asset | 2,325 | 1,576 | 751 | 768 | 0 | 1,469 |
| Total assets | 142,832 | 94,347 | 51,811 | 45,316 | 11,091 | 240,293 |
| Accounts payable | 2,090 | 2,108 | 970 | 868 | 329 | — |
| Accrued liabilities | 9,440 | 8,715 | 6,992 | 5,226 | 5,382 | 16,344 |
| Total current liabilities | 12,428 | 11,824 | 8,881 | 6,835 | 5,778 | 36,072 |
| Lease liability, non-current | 1,920 | 919 | — | 67 | 0 | 1,209 |
| Total liabilities | 14,613 | 12,743 | 8,881 | 6,902 | 5,778 | 37,281 |
| Accumulated deficit | (309,470) | (372,897) | (419,586) | (456,485) | (494,364) | (171,809) |
| Total stockholders' equity | 128,219 | 81,604 | 42,930 | 38,414 | 5,314 | 203,012 |
| Total liabilities and equity | 142,832 | 94,347 | 51,811 | 45,316 | 11,091 | 240,293 |
| Common shares outstanding (cover page)‡ thousands of shares | 515 | 523 | 642 | 645 | 645 | 27,557 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (June 2025); filings made before it reported them unadjusted.
- † Share count changed about 43x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (CBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (51,027) | (63,427) | (46,689) | (36,899) | (37,879) | (153,942) |
| Stock-based compensation | 6,902 | 6,087 | 3,858 | 3,524 | 4,698 | 13,300 |
| Net cash from operating activities | (39,242) | (57,490) | (46,457) | (34,880) | (31,098) | (71,532) |
| Purchases of property and equipment | 69 | 15 | 84 | 21 | 10 | 919 |
| Net cash from investing activities | (69) | (15) | (84) | (21) | 20 | (72,919) |
| Proceeds from issuing common stock | 17,825 | 10,699 | 4,157 | 28,707 | — | 0 |
| Net cash from financing activities | 18,144 | 10,724 | 4,157 | 28,824 | 5 | 322,984 |
| Net change in cash | (21,166) | (46,780) | (42,384) | (6,078) | (31,073) | 178,533 |
- † Share count changed about 43x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Crescent Biopharma | 171,593 | 0 | (19,463)* | 37.1M | 8.8 quarters | 10-QJun 30, 2026 |
| Omeros | 1,988 | 28,529 | 4,149* | 72.4M | — | 10-QJun 30, 2026 |
| Lexicon Pharmaceuticals | 40,924 | 692 | (9,192)* | 445.0M | 20.7 quarters | 10-QJun 30, 2026 |
| XOMA Royalty | 85,600 | 12,318 | 6,121 | 12.5M | — | 10-QMar 31, 2026 |
| 4D Molecular Therapeutics | 70,372 | 3,781 | (69,999)* | 55.2M | 5.2 quarters | 10-QJun 30, 2026 |
| Editas Medicine | 181,815 | 11,890 | (29,568)* | 153.6M | 7.2 quarters | 10-QJun 30, 2026 |
| Lineage Cell Therapeutics | 37,355 | 1,069 | (7,244)* | 252.9M | 7.0 quarters | 10-QJun 30, 2026 |
| Palvella Therapeutics | 187,803 | not reported | (12,845)* | 14.4M | 19.5 quarters | 10-QJun 30, 2026 |
| Esperion Therapeutics | 156,158 | 80,104 | (27,722) | 257.4M | 5.6 quarters | 10-QMar 31, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.